Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1853 1
1870 1
1994 1
1995 1
1996 2
1997 5
1999 1
2000 1
2001 1
2002 5
2003 3
2004 5
2005 3
2006 5
2007 4
2008 3
2009 1
2010 3
2011 10
2012 3
2014 8
2015 6
2016 5
2017 8
2018 6
2019 2
2020 6
2021 4
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27412828

101 results

Results by year

Filters applied: . Clear all
Page 1
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.
Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlová M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicová J, Skrha J, Taton J, Grzeszczak W, Crepaldi G. Gambaro G, et al. J Am Soc Nephrol. 2002 Jun;13(6):1615-25. doi: 10.1097/01.asn.0000014254.87188.e5. J Am Soc Nephrol. 2002. PMID: 12039991 Clinical Trial.
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Cherney DZI, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666775
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB; Collaborative Study Group. Heerspink HL, et al. Nephrol Dial Transplant. 2008 Jun;23(6):1946-54. doi: 10.1093/ndt/gfm893. Epub 2007 Dec 18. Nephrol Dial Transplant. 2008. PMID: 18089623 Clinical Trial.
Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J; Collaborative Study Group. Lambers Heerspink HJ, et al. Diabet Med. 2007 Nov;24(11):1290-5. doi: 10.1111/j.1464-5491.2007.02249.x. Diabet Med. 2007. PMID: 17956455 Clinical Trial.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; Collaborative Study Group. Packham DK, et al. J Am Soc Nephrol. 2012 Jan;23(1):123-30. doi: 10.1681/ASN.2011040378. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034636 Free PMC article. Clinical Trial.
101 results